The Efficiency of Telemedicine to Optimize Metabolic Control in Patients With Diabetes in Turkey: Preliminary Results From The Randomised Controlled Telediab Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Telemedicine
- Sponsor
- Istanbul University
- Enrollment
- 200
- Primary Endpoint
- Weight
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The direct and indirect costs of treating diabetes are high. 10-15% of the health budgets of many countries are spent on diabetes treatment. Most of these expenses are due to the treatment and follow-up costs of complications seen in patients who are not well monitored and whose metabolic control is not achieved. the rapid increase in diabetes causes polyclinic and hospital services to become more intense. Despite the increasing number of patients, both performance and due to non-physician occupational groups' insufficiency (Diabetes Dietician, Diabetes Nurse), patients can only be given an appointment once a year, and patients cannot be allocated sufficient time during the appointment. Since these problems are valid worldwide, Telemedicine programs are designed to provide easy, cheap, and practical follow-up and treatment of many chronic diseases in various states of the USA and many developed European countries.
Detailed Description
The project is designed as a randomized controlled trial with approximately 100 subjects receiving a telemedicine intervention and approximately 100 receiving usual care. Eligibility requires having diabetes and being a Medicare beneficiary. This program, called "TeleDiab" for the first time in our country, was designed in cooperation with the Istanbul University Rectorate and the local telecommunication company Turkcell. Its implementation was carried out as a pilot project in the Department of Endocrinology and Metabolic Diseases of Istanbul Medical Faculty in the follow-up and treatment of diabetic patients. Subjects are randomized to receive telemedicine case management or usual care for diabetes. This project, it is aimed to evaluate the "TeleDiab" program developed for use in diabetic patients in terms of applicability, practicality, effectiveness, and cost-effectiveness. In this way, it was aimed to compare the electronically followed patient group with a similar patient group routinely followed in terms of glycemic control, treatment compliance, complications, and comorbid diseases 6 months and 1 year later. The intervention utilizes a home telemedicine unit (HTU). The HTU is a specially designed, web-enabled device with a data port connected to a home glucometer and home blood pressure cuff whereby measurements obtained with these devices can be directly uploaded to a computer database. A diabetes nurse and a practitioner case manager interact regularly with intervention participants through videoconference via the HTU.
Investigators
Fulya Turker
MD, PhD; Academician; Principle Investigator
Istanbul University
Eligibility Criteria
Inclusion Criteria
- •for TeleDiab group:
- •Have known Type 1 diabetes for at least 3 months or Type 2 diabetes using basal-bolus insulin
- •Being between the ages of 18-65
- •Istanbul University Istanbul Medical Faculty Internal Diseases Department, Endocrinology and Being registered and being monitored in the Metabolic Diseases BD, Diabetes Outpatient Clinic
- •To be able to measure blood glucose from the fingertip (couplings) at home
- •To be able to measure blood pressure at home
- •To be able to use computers and smartphones
- •Instead of electronic directives and recommendations of the physician or diabetes nurse be able to bring
- •Agree to participate in the study.
- •for the control group:
Exclusion Criteria
- •\<18 and\> 65years old
- •Presence of Type 1 diabetes for less than 3 months or Type 2 diabetes not using insulin
Outcomes
Primary Outcomes
Weight
Time Frame: Change in baseline weight (kg) measurement frequency at 24th month
Capillary glucose levels changes
Time Frame: Change in baseline capillary glucose levels (mg/dl) at 24th month
Home blood glucose measurement frequency
Time Frame: Change in baseline home blood glucose measurement frequency at 24th month
A1c measurement
Time Frame: Change in baseline A1c (%) measurement frequency at 24th month
BMI
Time Frame: Change in baseline BMI (kg/m2) measurement frequency at 24th month
Secondary Outcomes
- Number of patients who developed new comorbidities in 24 months(Change from baseline to 24 months)
- The number of patients who added insulin to their oral antidiabetic medication or switched to oral antidiabetic medication by discontinuing insulin(Change from baseline to 24 months)
- Number of patients developing new diabetes complications within 24 months(Change from baseline to 24 months)